SCHEMBL1809222

SCHEMBL1809222

OCC1C[C@H]2C=CC1C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2282146 1.00
SCHEMBL16898634 1.00
SCHEMBL1809216 1.00
SCHEMBL33077 1.00
SCHEMBL14857811 1.00
SCHEMBL14857813 1.00
SCHEMBL1809220 1.00
SCHEMBL9473130 1.00
SCHEMBL20721709 1.00
SCHEMBL4132180 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2207766-A1 NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE Abbott Products GmbH (DE) 2010-07-21 EP claimed
WO-2009050252-A1 NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE SOLVAY PHARMACEUTICALS GMBH (DE) 2009-04-23 WO claimed
US-20090104126-A1 Sulfamate Compounds and Uses Thereof SOLVAY PHARMACEUTICALS GMBH (DE) 2009-04-23 US claimed
EP-4682148-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2026-01-21 EP disclosed
US-20250161318-A1 SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT ABBVIE INC (US) 2025-05-22 US disclosed
US-20250019364-A1 APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2025-01-16 US disclosed
EP-4474383-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2024-12-11 EP disclosed
US-11897864-B2 Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2024-02-13 US disclosed
US-20240043404-A1 APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2024-02-08 US disclosed
EP-2435432-B3 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE IRELAND UNLIMITED CO (BM) 2023-10-25 EP disclosed
EP-4218731-A2 MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT AbbVie Ireland Unlimited Company (IE) 2023-08-02 EP disclosed
US-20120277210-A1 SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT ABBOTT LABORATORIES (US) 2012-11-01 US disclosed
EP-2502941-A1 Heterobifunctional poly (ethylene glycol) and uses thereof Intezyne Technologies Inc. (US) 2012-09-26 EP disclosed
US-20120190688-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BRUNCKO MILAN (US) 2012-07-26 US disclosed
US-20120108590-A1 MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT ABBOTT LABORATORIES (US) 2012-05-03 US disclosed
US-20110124628-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2011-05-26 US disclosed
US-20100305122-A1 APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-12-02 US disclosed
EP-2207766-A1 NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE Abbott Products GmbH (DE) 2010-07-21 EP disclosed
WO-2009050252-A1 NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE SOLVAY PHARMACEUTICALS GMBH (DE) 2009-04-23 WO disclosed
US-20090104126-A1 Sulfamate Compounds and Uses Thereof SOLVAY PHARMACEUTICALS GMBH (DE) 2009-04-23 US disclosed